Point-of-Care Anti–CD19-CAR T-cell Therapy Induces Renal Remission in Refractory Myeloperoxidase–Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Authors:
- Christian R. Schultze-FloreyCSChristian R. Schultze-Florey
- Vega GödeckeVGVega Gödecke
- Lisa KnollLKLisa Knoll
- Krasimira AleksandrovaKAKrasimira Aleksandrova
- Lubomir ArsenievLALubomir Arseniev
- Jana LeiseJLJana Leise
- Stephan KlößSKStephan Klöß
- Kalin StoyanovKSKalin Stoyanov
- Rodrigo Gutierrez JaureguiRJRodrigo Gutierrez Jauregui
- Jan Hinrich BräsenJBJan Hinrich Bräsen
- Bernhard M.W. SchmidtBSBernhard M.W. Schmidt
- Florian H. HeidelFHFlorian H. Heidel
Open Access
- 16 May 2025
- journal article
- Published by Elsevier in Kidney International Reports
- Vol. 10 (7) , 2491-2493
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Anti-CD19 CAR-T cell therapy for acquired hemophilia ALeukemia, 2025
- Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitisAnnals of the Rheumatic Diseases, 2025
- CD19-CAR T-cell therapy induces deep tissue depletion of B cellsAnnals of the Rheumatic Diseases, 2024
- CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-upNew England Journal of Medicine, 2024